Introduction
DYT1 dystonia is an autosomal-dominant disease invariably caused by a three base pair deletion in the TOR1A gene. This mutation removes a codon (Dgag; DE) that normally encodes a glutamic acid residue in the C terminus of torsinA (Ozelius et al., 1997) . Although torsinA is broadly expressed (Ozelius et al., 1997) , DYT1 dystonia manifests as abnormal, involuntary twisting movements reflecting selective dysfunction of CNS motor circuits. In addition, the disease typically begins during a discrete period of early childhood (Berardelli et al., 1998; Bressman et al., 1994; Fahn et al., 1987) , suggesting that a developmental abnormality leads to the altered CNS activity of DYT1 dystonia. These characteristics suggest that understanding the pathogenesis of DYT1 dystonia may provide unique insight into processes involved in neuronal development and function.
TorsinA is a peripheral membrane protein that resides in the lumen of the endoplasmic reticulum (Kustedjo et al., 2000; Liu et al., 2003) . TorsinA is a member of the AAA+ (ATPase associated with different cellular activities) protein family; these proteins typically function as oligomers and use the energy of ATP hydrolysis to disassemble protein complexes. AAA+ proteins participate in a diverse range of biological functions, including membrane trafficking, powering cellular motors, and protein chaperone activities (Neuwald et al., 1999; Ogura and Wilkinson, 2001; Patel and Latterich, 1998; Vale, 2000) . Although inclusion in the AAA+ protein family provides little insight into the cellular role of torsinA, several observations indicate that the nuclear envelope lumen is a site of torsinA activity (Gerace, 2004; Gonzalez-Alegre and Paulson, 2004; Goodchild and Dauer, 2004; Naismith et al., 2004) . Consistent with this notion, torsinA interacts with the luminal domain of the inner nuclear membrane protein lamina-associated polypeptide 1 (LAP1) (Goodchild and Dauer, 2005) . In addition, disease-associated DE-torsinA accumulates abnormally in the nuclear envelope (Gonzalez-Alegre and Paulson, 2004; Goodchild and Dauer, 2004) , suggesting that abnormal interaction between DE-torsinA and a nuclear envelope binding partner may contribute to disease pathogenesis.
Despite this progress in understanding the biology of torsinA, there are no experiments demonstrating an effect of wild-type or DE-torsinA on nuclear envelope function, and existing animal models have provided conflicting information as to whether DE-torsinA is associated with the nuclear envelope in vivo (Cao et al., 2005; Goodchild and Dauer, 2004; Koh et al., 2004; Sharma et al., 2005; Shashidharan et al., 2005) . In addition, DE-torsinA abnormally accumulates in the nuclear envelope of both neuronal and nonneuronal cells, calling into question the relationship between nuclear envelope function and disease pathogenesis. Furthermore, although models of disease pathogenesis depend critically on understanding whether a pathogenic mutation confers a gain or loss of function to the disease protein, the effect of the Dgag mutation on torsinA function is unclear. To address these limitations, we generated torsinA null and Dgag knockin mice and have used these animals to explore the normal cellular role of torsinA and the effect of the DYT1 mutation on torsinA function.
Results
The DYT1 Dystonia Mutation Inhibits TorsinA Function We used gene targeting to generate torsinA null (Tor1a 2/2 ) ( Figure 1B ) and Dgag knockin (Tor1a Dgag/Dgag ) mice ( Figure 1C ). The DYT1 knockin mice contain the Dgag mutation in the endogenous mouse Tor1a gene ( Figures 1C and 1D ). To prevent nonspecific effects from the PGK-neomycin resistance selection cassette, both lines of mice were crossed with transgenic Cre recombinase mice that excise the cassette from the germ line (see the Supplemental Data available with this article online). and Tor1a Dgag/Dgag animals move, breath, and respond to stimuli, but they typically fail to feed or vocalize. Although torsinA is ubiquitously expressed at birth *Correspondence: wtd3@columbia.edu ( Figure 1F ), Tor1a 2/2 and Tor1a Dgag/Dgag pups display no obvious developmental abnormalities ( Figure 1G ).
The striking similarity between the Tor1a 2/2 and Tor1a Dgag/Dgag animals suggested that Tor1a Dgag may be a loss-of-function allele. However, it remained possible that this comparison was confounded by genetic background or that the Tor1a
Dgag allele might produce more mechanistically complex effects than a simple loss of function. Thus, we formally tested whether Tor1a
Dgag was a loss-of-function allele by crossing it onto the null background, generating Tor1a
Dgag/2 animals. Similar to Tor1a 2/2 and Tor1a Dgag/Dgag animals, Tor1a
Dgag/2 mice appeared normally developed, but failed to survive past 48 hr. Thus, our genetic analysis suggests strongly that Tor1a
Dgag is a loss-of-function allele.
To test whether the Dgag mutation might cause this loss of function by altering the stability of torsinA protein, we next measured torsinA protein levels in the Tor1a mutant mice. We found that steady-state levels of torsinA decrease with Tor1a
Dgag gene dosage in all tissues examined (Figure 2A ), even though homozygous Tor1a
Dgag/Dgag knockin mice have normal levels of torsinA mRNA ( Figure 2C ). We subsequently assessed whether torsinA protein levels are also reduced by the Dgag mutation in the human disease. Similar to our results in mice, there is less torsinA in skin fibroblasts derived from DYT1 patients (heterozygous for Dgag) compared with controls ( Figure 2D ). These observations indicate that Tor1a Dgag animals accurately model some of the molecular features of DYT1 dystonia and suggest that loss of torsinA activity may contribute to the neurological symptoms of the disease.
CNS Structure Is Normal in Tor1a Mutant Mice
We next explored the effects of torsinA deficiency on the developing CNS of Tor1a 2/2 and Tor1a Dgag/Dgag mice at embryonic day 18 (E18), typically the final day of mouse gestation. The brains of homozygous mutant animals appear grossly normal ( Figure 3A ), exhibiting normal neocortical layering ( Figure 3B ) and spinal cord development ( Figure 3C ). In addition, normal levels of synapsin indicate that gross synaptic development in the spinal cord, the most mature area of the CNS, is comparable between Tor1a 2/2 and Tor1a Dgag/Dgag mice and their wild-type littermates ( Figure 3D ). Because dopaminergic dysfunction is implicated in other forms of dystonia (Bandmann and Wood, 2002) , we examined the nigrostriatal dopaminergic system of E18 embryos. The dopaminergic projections to the striatum appeared normal in both homozygous mutants ( Figure 3E ), further illustrating normal circuitry development in these torsinA mutant mice. and Dauer, 2004; Goodchild and Dauer, 2005; Naismith et al., 2004) . Furthermore, disease mutant torsinA abnormally accumulates in the nuclear envelope in cells derived from DYT1 dystonia patients (Goodchild and Dauer, 2004 ). These observations suggest that nuclear envelope dysfunction may contribute to disease pathogenesis in DYT1 dystonia. We therefore examined the nuclear envelope in both lines of torsinA mutant mice. This analysis revealed severe abnormalities of nuclear envelope ultrastructure in the CNS of both Tor1a
and Tor1a Dgag/Dgag mice ( Figures 4A and 4B ), while the main endoplasmic reticulum appears relatively unaffected ( Figure 4C ). In both lines, the lumen of the neuronal nuclear envelope contains large numbers of vesicles (Figures 4A and 4B ) that appear to derive from the inner nuclear membrane (arrowhead in Figure 4E ).
The similarly appearing membrane abnormalities of Tor1a 2/2 and Tor1a Dgag/Dgag neurons again suggested that the Dgag mutation is a loss-of-function allele, prompting us to examine the nuclear envelope morphology of Tor1a
, and Tor1a
Dgag/+ animals. Nuclear membrane abnormalities indistinguishable from those in Tor1a 2/2 and Tor1a Dgag/Dgag animals were present in the CNS of Tor1a
Dgag/2 mice. However, nuclear membrane abnormalities were not present in Tor1a
Dgag/+ heterozygous animals ( Figure 4F ), suggesting that there is sufficient torsinA function to maintain normal nuclear membrane morphology in these animals. We exploited the presence of this cellular phenotype to carefully test whether the effect of the DYT1 mutation was mediated entirely through its effect on protein levels (Figure 2 ) or whether it also affects the activity of DE-torsinA protein. To explore this question, we compared the steady-state levels of torsinA in Tor1a
Dgag/Dgag brain with those of unaffected Tor1a
animals. Although both of these mice have similar steady-state levels of torsinA (Figures 4G and 2A) , the knockin mice exhibit the complete null phenotype, while the heterozygous knockouts do not. Thus DE-torsinA appears to be a hypoactive, perhaps inactive, form of torsinA. Interestingly, the nuclear membranes of blood-brain barrier associated cells (both pericytes and endothelial cells) appeared normal ( Figure 5A ), despite the presence of abnormalities in adjacent neurons (asterisk in Figure 5A) . We further assessed other CNS cell types and found that both astrocytes and oligodendrocytes also appeared normal ( Figure 5B ). We also failed to identify nuclear envelope changes in any non-nervous system tissue, despite examining connective, epithelial, and muscle cell types ( Figure 5C ). Thus, the nuclear envelope abnormalities appear to occur specifically in neurons, similar to the tissue selectivity characteristic of DYT1 dystonia.
To explore whether torsinA function might be particularly important for certain neuronal populations, we performed a broad assessment of nuclear envelope ultrastructure in the CNS of E18 Tor1a 2/2 and Tor1a
Dgag/Dgag mice. Nuclear envelope abnormalities were observed in multiple areas of the CNS, including neurons of the spinal cord, pons, frontal cortex, and hippocampus. Although the presence of luminal vesicles was widespread, we observed that large ventral horn neurons were particularly severely affected. Similar to these ultrastructural abnormalities, light microscopic analysis revealed that the nuclear shape of Tor1a 2/2 ventral horn neurons is abnormally convoluted compared with wild-type neurons ( Figures 6A and 6B) . However, the nuclear lamina remained intact in even these severely affected cells. In addition, it appears that nuclear lamins are not incorporated into the luminal vesicles because the lamina thickness did not differ between wild-type and Tor1a 2/2 ventral horn neurons. Despite the occurrence of luminal vesicles in other spinal cord neurons, we were unable to identify abnormalities in the nuclear lamina anywhere other than the worst affected ventral horn neurons ( Figures 6C and 6D ).
Nuclear Membrane Abnormalities Worsen with Neuronal Maturation Our broad assessment of nuclear envelope ultrastructure throughout the CNS also revealed that the severity and number of affected cells clearly increases in a rostral-caudal gradient, a pattern that mirrors the progression of CNS development. This apparent developmental dependence prompted us to focus on events occurring at the nuclear membrane during neuronal development. Interestingly, we never observed vesicles in the nuclear membranes of migrating cortical (E15) or spinal cord (E12) neurons; the nuclear membranes of all migrating cells were morphologically normal ( Figure 7A and data not shown). While nuclear envelope vesicles were present at these relatively early points in development (E12 ventral spinal cord), they were observed exclusively in postmigratory cells ( Figure 7B ). The nucleus of migrating neurons is characteristically elongate and irregularly shaped, but the nuclei of postmigratory neurons are more rounded (Peters et al., 1991; Rakic et al., 1974) ( Figure 7C ). This transformation of nuclear morphology may reflect that different physical properties are required of migrating nuclei compared to the nuclei of mature postmigratory cells. These data suggested that torsinA or its interacting proteins might participate in the developmental transformation of nuclear shape. To begin to explore this notion, we examined the expression of torsinA and the torsinA-interacting proteins LAP1 and LULL1 during spinal cord development and maturation ( Figure 7D ). This analysis revealed that the expression of the largest LAP1 isoform, LAP1A, is upregulated at approximately the same time that nuclear envelope vesicles begin to form (Figure 7D) . However, neither LAP1 nor LULL1 expression is altered in Tor1a 2/2 spinal cord ( Figure 7E ), despite the occurrence of nuclear envelope abnormalities in this tissue.
We next examined the spinal cord of Tor1a 2/2 E15 and E18 embryos to assess the relationship of nuclear envelope abnormalities to postmigratory neuronal maturation. Ventral regions of the spinal cord develop several days prior to dorsal areas (Altman and Bayer, 2001 ). Similar to this developmental gradient, we observed that at both ages there was a greater percentage of cells with nuclear envelope abnormalities in ventral compared to dorsal spinal cord (Figures 6 and 8A-8H) . Furthermore, the severity of membrane abnormalities (number of vesicles/cell) worsened between E15 and E18 in both dorsal and ventral regions. The progressive increase in vesicle number suggests that the nuclear envelope retains and accumulates luminal vesicles over time. Consequently, it appears that nuclear membrane abnormalities develop following migration and worsen concurrent with subsequent events of neuronal maturation, including the transformation of nuclear shape.
Discussion
These data provide novel insight into the molecular mechanism of DYT1 dystonia, demonstrating that the DYT1 Dgag mutation acts through at least two independent mechanisms to impair torsinA function. Our data also demonstrate a unique requirement for torsinA function in neural tissue, the only tissue affected in the disease. Taken together, these findings suggest that loss , and Tor1a Dgag/Dgag striata illustrates the normal development of nigrostriatal dopaminergic projections. CX, cortex; Str, striatum.
of torsinA function within the neuronal nuclear envelope may contribute to the pathogenesis of DYT1 dystonia.
The strikingly similar phenotypes of Tor1a 2/2 , Tor1a
Dgag/2 , and Tor1a
Dgag/Dgag animals demonstrates that Tor1a
Dgag is a loss-of-function allele. One mechanism by which the mutation causes loss of function is to reduce the steady-state levels of torsinA. This conclusion is supported by data showing a Tor1a
Dgag -related gene dosage effect on torsinA levels in mice and decreased torsinA protein in skin fibroblasts derived from DYT1 patients. This effect on torsinA levels appears to be mediated entirely at the protein level, as Tor1a
Dgag/Dgag mice have normal levels of torsinA mRNA. We have previously shown that torsinA is abnormally located in the nuclear envelope of fibroblasts derived from DYT1 patients (Goodchild and Dauer, 2004) , suggesting that DE-torsinA protein remains in these cells. However, it is unclear whether lower torsinA levels reflect a selective decrease of DE-torsinA or whether the presence of DE-torsinA leads to a reduction of both wild-type and 2/2 and Tor1a Dgag/Dgag spinal cord neurons shows vesicles in the nuclear envelope lumen (left; arrowhead points to a vesicle budding from the inner nuclear membrane) and outer nuclear membrane envelopment (center). Scale bars, 1 mm. (F) Nuclear membrane abnormalities are present in the spinal cord of E18 Tor1a
Dgag/2 but not Tor1a Dgag/+ and Tor1a +/2 animals. Scale bars, 1 mm. (G) Similar steady-state levels of torsinA in the brains of Tor1a +/2 and Tor1a Dgag/Dgag mice. Lysates extracted with 1% SDS from individual E18 Tor1a mutant mice were probed with anti-torsinA and b-actin antibodies.
DE-torsinA. Unfortunately, currently available antisera are unable to distinguish between the single amino acid difference of wild-type and mutant protein, precluding further study of this issue at this time.
Independent from its effect on torsinA levels, our data also demonstrate that the DYT1 Dgag mutation results in an intrinsically hypoactive, potentially inactive, form of torsinA. Central to this conclusion is the comparison between the Tor1a +/2 and Tor1a Dgag/Dgag animals. While torsinA levels are similar in the nervous system of Tor1a +/2 and Tor1a Dgag/Dgag mice, only Tor1a
Dgag/Dgag mice display the characteristics of torsinA loss, namely perinatal lethality and neuronal nuclear membrane abnormalities. Thus DE-torsinA is less active than the wild-type protein. In fact, DE-torsinA in Tor1a
Dgag/Dgag animals is unable to ameliorate any effect associated with the complete absence of torsinA, indicating that it could be inactive. Several lines of evidence from in vitro studies of torsinA suggest that a third mechanism may also reduce torsinA activity in the heterozygous state of DYT1 dystonia. AAA+ proteins typically operate as oligomers (Neuwald et al., 1999; Ogura and Wilkinson, 2001; Patel and Latterich, 1998; Vale, 2000) , and it has been shown that wild-type and DE-torsinA can coassemble into heterooligomers. Specifically, wild-type and DE-torsinA coimmunoprecipitate (Torres et al., 2004) , and the presence of DE-torsinA causes wild-type protein to relocate to the nuclear envelope (Goodchild and Dauer, 2004) . Thus, our finding that DE-torsinA is a hypoactive torsinA isoform is consistent with the hypothesis that DE-torsinA expression in DYT1 dystonia further reduces torsinA activity via a dominant-negative mechanism. However, our experiments do not specifically address this issue.
Previously described animal models of DYT1 dystonia have been mostly limited to transgenic overexpression of DE-torsinA (Cao et al., 2005; Koh et al., 2004; Sharma et al., 2005; Shashidharan et al., 2005; Dang et al., 2005) . While overexpressing DE-torsinA on a wild-type background has led to varying behavioral and cellular effects, none of these studies addressed the effect of the DYT1 mutation on normal torsinA function or assessed nuclear envelope ultrastructure. Although it is possible to model a dominant effect in a transgenic study, it is not generally possible to distinguish between a dominant gain or loss of function in these experiments. In addition, the other aspects of the Dgag mutation described here (e.g., decreased total levels of torsinA protein) are not modeled by transgenic DE-torsinA expression. To date, all transgenic animals have been viable, unlike Tor1a
Dgag/2 and Tor1a Dgag/Dgag mice, and the nuclear membrane abnormalities seen here have not been reported. Our data also indicate a developmental requirement for torsinA function, so differences between transgenic and gene-targeted models might relate to the developmental timing of transgene expression.
The multiple mechanisms by which the DYT1 mutation can decrease torsinA function, including the potential for a dominant-negative mechanism, raise the question of why nuclear envelope vesicles do not develop in 2/2 neuroglial lack nuclear envelope vesicles. Images show a cultured forebrain astrocyte and an oligodendrocyte from spinal cord white matter. Scale bars, 500 nm. (C) Tor1a 2/2 connective, epithelial, and muscle cell types lack nuclear envelope vesicles. Also note the normal appearance of rough endoplasmic reticulum (rER) in a Tor1a 2/2 hepatocyte. Scale bars, 500 nm.
Tor1a
Dgag/+ mice. One possibility is that these morphological abnormalities only develop in the complete absence of torsinA activity and are therefore not a sensitive measure of torsinA function. This notion is supported by the finding that nuclear envelope vesicles do not occur in heterozygous null mice, which have w50% of normal torsinA levels. Complete loss of torsinA activity is unlikely in Tor1a
Dgag/+ mice (or DYT1 patients) because of the presence of wild-type torsinA. Unfortunately, it will not be possible to definitively determine whether DEtorsinA exerts a dominant-negative effect until the normal cellular activity of torsinA can be quantitatively assessed.
The notion that there is a relatively mild biological disturbance in DYT1 dystonia is consistent with clinical features of the disease. The DYT1 mutation is roughly 30% penetrant (w70% of Dgag carriers do not develop dystonia), and the majority of patients who do develop dystonic symptoms exhibit relatively localized symptoms. In fact, only about 10% of Dgag carriers develop debilitating dystonia. These observations suggest that DYT1 patients or heterozygous knockin mice are likely to exhibit a rather subtle cellular disturbance. Independent of the severity of the cellular abnormality underlying DYT1 dystonia, the fact that the multiple effects of the Dgag mutation likely combine to impair torsinA activity argues that the normal cellular action of torsinA is reduced in DYT1 dystonia.
Our observations indicate that the nuclear envelope is a key site of torsinA activity, raising the possibility that this organelle may be preferentially disrupted in DYT1 patients. Two features of the nuclear membrane phenotype described here are consistent with the notion that nuclear envelope dysfunction contributes to the symptoms of DYT1 dystonia. First, the symptoms of the disease and the nuclear membrane vesicles are both exclusively neuronal, despite the widespread expression of torsinA. Second, the onset of disease symptoms and the appearance of nuclear envelope vesicles both exhibit a developmental dependence. Thus, we hypothesize that a more moderate insult to the biological pathway responsible for nuclear membrane vesicle formation may contribute to the symptoms of DYT1 dystonia.
The nuclear envelope and endoplasmic reticulum form a continuous membrane system. Nuclear pores and lamin binding transmembrane proteins are specifically found in the nuclear envelope, but other functions and proteins occur in both areas. The membrane abnormalities caused by torsinA deficiency appear to be specifically located in the nuclear envelope lumen, and the peripheral endoplasmic reticulum generally appears normal. However, it is possible that torsinA mutation disrupts a process common to the endoplasmic reticulum and nuclear envelope.
The possibility that a specialized aspect of neuronal development requires proteins of the nuclear envelope has not been previously considered. We find that nuclear envelope vesicles develop coincident with postmigratory transformation of neuronal nuclear morphology, raising the possibility that torsinA normally participates in this poorly understood process. Consistent with this notion, a number of AAA+ proteins are involved in membrane-localized events such as membrane fusion (Neuwald et al., 1999; Ogura and Wilkinson, 2001; Patel and Latterich, 1998; Vale, 2000) . Furthermore, torsinA interacts with the luminal domain of the integral inner nuclear membrane protein LAP1 (Goodchild and Dauer, 2005) , whose structural features and links to nuclear lamins (Martin et al., 1995) are consistent with a potential role in this process. It is also possible that torsinA is involved in nucleokinesis, a key component of neuronal migration, in which coupling of the nucleus, centrosome, and microtubules are used to generate nuclear movement (Tsai and Gleeson, 2005) . Interestingly, a C. elegans torsinA homolog, ooc-5, is important for the related process of nuclear rotation in early stages of embryo development (Basham and Rose, 1999) . While neuronal migration appears normal in the torsinA mutants, torsinA may be involved in disassembly of the nucleokinesis machinery, the uncoordinated dismantling of which could lead to abnormal shear forces.
Taken together, our data highlight that the nuclear envelope undergoes a dynamic reorganization during neuronal maturation and suggest that alterations in this process may underlie human neurodevelopmental disease. spinal cord lysates.
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Experimental Procedures
Characterization of Tor1a Mutant Mice All Tor1a mutant embryos were delivered by caesarian section from timed pregnant female mice housed on a standard light-dark cycle. The day following overnight mating was designated as embryonic day 0 (E0). Routine histological evaluation was performed on sections of formaldehyde-fixed embryos stained with haematoxylin and eosin. Embryos were prepared for immunohistochemistry by transcardial perfusion with 4% formaldehyde. Tissue was cryoprotected using 30% sucrose, frozen, and 20 mm sections stored at -80ºC until required. For immunolabeling visualized using peroxidase and 3, 3 0 -diaminobenzidine (DAB), sections were post-fixed for 10 min, incubated in 0.3% H 2 O 2 , incubated with the avidin-biotin kit (Vector Labs), and permeabilized using 0.25% Triton X-100 in PBS, including 10% normal donkey serum. Primary antibody incubation was performed overnight at 4ºC in permeabilization solution. The following day, sections were washed in PBS, incubated for 1 hr in biotinylated secondary antibody (Jackson ImmunoResearch), washed, incubated in ABC reagent (Vector Labs), and developed using DAB substrate (Vector Labs). Immunofluorescent labeling was performed similarly, except that sections were immediately permeabilized and blocked following fixation. Primary antibody incubations were performed at 4ºC overnight, then sections were washed and incubated with Cy3-conjugated secondary antibodies (Jackson ImmunoResearch). Sections were subsequently washed, incubated with NeuroTrace 500/525 green fluorescent Nissl stain (Invitrogen/Molecular Probes) according to the manufacturer's instructions, and coverslip mounted using Vectashield with DAPI (Vector Laboratories). Images were obtained using a LSM510 multiphoton microscope (Zeiss). All animal experiments were performed in accordance with National Health Guidelines for the use of live animals, and the animal protocol was approved by the Institutional Animal Care and Use Committee of Columbia University.
Western and Northern Blotting
Protein lysates were produced by sonicating tissues in 100 mM TrisHCl buffer (pH 8.0) containing 1% SDS, 150 mM NaCl, and complete protease inhibitor cocktail (Sigma). Protein concentration was determined using BCA assay (Pierce). Lysates were diluted in Laemmli sample buffer and used in SDS-PAGE. Total RNA was extracted from tissue using Trizol Reagent (Invitrogen) according to the manufacturer's instructions. Northern blots were hybridized using ExpressHyb solution (Clontech) and 32 P-labeled DNA probes. Fulllength coding cDNA sequences for mouse torsinA were used as templates in random priming reactions using Random Priming Kit (Roche).
Cell Culture
Mouse embryonic fibroblasts (MEF) were prepared after removing the head and liver from E13 embryos. Tissue was disrupted by three passages through an 18 gauge needle, and cells were plated in DMEM containing 15% fetal bovine serum (FBS). Astrocytes were prepared from E18 frontal cortex that was minced, incubated in 0.25% trypsin for 15 min and dissociated by passaging through fire-polished glass pipettes of decreasing diameter. Cells were plated and grown in MEM media containing 10% FBS.
Antibodies
Rabbit anti-torsinA was a kind gift from Brett Lauring (Columbia University). Rabbit polyclonal antibodies against mouse LAP1 and LULL1 have been described previously (Goodchild and Dauer, 2005) . Monoclonal anti-dopamine transporter and rabbit anti-synapsin were from Chemicon. Mouse monoclonal anti-myc was from Clontech, b-actin from Sigma, and anti-GAPH was from Ambion. Goat polyclonal anti-laminB was from Santa-Cruz.
Ultrastructural Analysis
Tissue was prepared by transcardial perfusion of embryos with 4% paraformaldehyde/3% glutaraldehyde in 100 mM sodium phosphate buffer (pH 7.4), followed by postfixation in the same solution. Cultured fibroblasts and astrocytes were also fixed in this solution, then scraped from the dish with a Teflon scrapper and pelleted before dicing into small pieces. All samples were postfixed with 1% osmium tetroxide in 0.1 M cacodylate buffer (pH 7.4) on ice for 1 hr. Samples were then treated with 0.5% aqueous uranyl acetate, dehydrated in graded alcohol, treated with propylene oxide, and embedded in Embed 812 (Electron Microscopy Sciences, Fort Washington, PA) The resin was polymerized in a 60 degree oven for 2-3 days. Sections were cut with a Dupont diamond knife on Reichert-Jung UltraCut E ultramicrotome, collected on copper grids, and doubly stained with saturated aqueous uranyl acetate and lead citrate. Ultrathin sections were viewed using a JEM-1200EX electron microscope manufactured by JEOL, Inc.
Supplemental Data
A detailed description of molecular biology methods used to generate Tor1a targeted mice is provided in the Supplemental Material and Supplemental Figure S1 at http://www.neuron.org/cgi/content/ full/48/6/923/DC1/.
